The Technical AnalystExchange: PNK Industry: Biotechnology
Propanc Biopharma, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0008
America/New_York / 3 mai 2024 @ 15:03
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 630.72 mill |
| EPS: | -0.0100 |
| P/E: | -0.0800 |
| Earnings Date: | May 15, 2023 |
| SharesOutstanding: | 3 288 400 mill |
| Avg Daily Volume: | 4.53 mill |
| RATING 2024-05-03 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0800 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.0800 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ -0.0002 - 0.0018 ( +/- 125.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-07-05 | Zelinger Josef | Buy | 15 000 000 | Common Stock Purchase Warrant |
| 2021-08-17 | Kenyon Julian Norman | Buy | 3 420 000 | Common stock, par value $0.001 |
| 2021-08-17 | Nathanielsz James Andrew | Buy | 5 928 000 | Common stock, par value $0.001 |
| 2021-08-17 | Nathanielsz James Andrew | Buy | 2 800 000 | Common stock, par value $0.001 |
| 2021-08-17 | Zelinger Josef | Sell | 0 | Common stock, par value $0.001 |
| INSIDER POWER |
|---|
| 100.00 |
| Last 22 transactions |
| Buy: 280 061 820 | Sell: 580 500 |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0008 (0.00% ) |
| Volume | 14.68 mill |
| Avg. Vol. | 4.53 mill |
| % of Avg. Vol | 323.80 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PPCB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PPCB
Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.